Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - Nextgen Biosciences Inc. - Exhibit 10.6

EXHIBIT 10.6

NextGen Bioscience, Inc. 
(formerly Infrablue US Inc.) 
130
Shaftesbury Avenue 
London 
W1D 5EU

Westport Strategic Partners, Inc. 
110 E. Broward Blvd.,

Suite 1700, 
Ft. Lauderdale, 
Florida 33301

26th November, 2007

Dear. Mr. Safina,

Following our conversations and agreement to terminate the
contract dated 21st August, 2006 between Infrablue US Inc. and
Westport Strategic Partners, Inc. Please have the director of Westport Strategic
Partners, Inc. confirm and sign the below letter agreement.

Yours truly,

/s/ Mitchell Johnson

Mitchell Johnson
President – NextGen Bioscience Inc.
(formerly Infrablue US Inc.)

I, Joseph Safina am the Director and authorized
signatory of Westport Strategic Partners, Inc. I confirm that as at Monday
26th November, 2007 we have agreed to terminate the consulting
services agreement with Infrablue US Inc. with immediate effect. I also confirm
that upon receipt of 150,000 shares of NXGB.OB being issued to Westport
Strategic Partners, Inc. all debt earned by the Agreement dated August 21, 2006
will be written off. 

	 	/s/ Joseph Safina 
	Signed: 	________________________
	  	  
	Date: 	        26th
      November,
      2007Filed by Automated Filing Services Inc. (604) 609-0244 - Nextgen Biosciences Inc. - Exhibit 10.7

EXHIBIT 10.7

CONSULTANCY AGREEMENT

PARTIES

(1) NEXTGEN BIOSCIENCE INC., whose office is located at,
46 Aldgate High Street, EC3N 1AL London, U.K. (the “Company”)

(2) Dr Wang Chong, of Wangi Ltd. 16 The Atrium, 30
Vincent Square, London, SW 1P 2NW, UK (the “Consultant”)

WHEREAS

	(A) 	
      The Consultant has agreed to provide, for a period of two
      years, consultancy services to the Company in the area of scientific
      advice in connection with the business of the evaluation, acquisition and
      development of patents in the field of healthcare drug treatments offered
      by the Company and its associated companies (the “Business”).

	 	 
	(B) 	
      The parties have agreed that this agreement shall govern
      the terms of the services to be provided by the
  Consultant.

OPERATIVE PROVISIONS

	1. 	
      DURATION OF APPOINTMENT

	 	 	 
	1.1 	
      The Consultant shall continue to provide the consultancy
      service to the Company on the terms of this agreement for a term from
      1st December 2007 for a fixed term of two years unless or until
      terminated under the provisions of Clause 5.1 hereafter. The parties may
      extend the term of this Agreement for a further term of twelve months by
      mutual written agreement.

	 	 	 
	2. 	
      DUTIES

	 	 	 
	2.1 	
      The services of the Consultant shall comprise the giving
      of advice to the Company in the area of scientific advice via the
      Scientific Advisory Board of the Company (“Advisory Board” or “SAB”)) in
      connection with the Business and such other advisory services as may be
      agreed between the parties.

	 	 	 
	2.2 	
      The Consultant shall be accountable to the Company’s CEO
      and shall in performance of his role hereunder:

	 	 	 
		(a) 	
      Use his best endeavours to advise the Company via the
      Advisory Board when required in the areas described in 2.1
above;

	 	 	 
		(b) 	
      Conduct such travelling as shall be reasonably necessary
      to advise the Business;

	 	 	 
		(c) 	
      Carry out his duties in good faith and in proper and
      efficient manner;

	 	 	 
		(d) 	
      Conduct himself with propriety and not bring the Company
      into disrepute;

	 	 	 
		(e) 	
      Not have any authority to bind the Company in any way and
      shall not hold himself out either by words or conduct as being the agent
      of the Company;

	 	 	 
		(f) 	
      Act as a member of the Advisory Board of the Company,
      attending meetings where possible of such advisory board when held in
      London or other cities in Europe; and

	 	(g) 	
      Not misrepresent the Company to any
  person.

	3. 	
      FEES

	 	 	 	 
	3.1 	
      The Consultant shall be not entitled to receive from the
      Company any fixed cash fees for the services outlined herein, but shall be
      entitled to receive reimbursement of any and all expenses properly
      incurred in performing his duties hereunder.

	 	 	 	 
	3.2 	
      The Consultant will receive, as payment in kind from the
      Company, in respect of his services under this Agreement, the issue to him
      of 100,000 shares in the Company. The Consultant undertakes that the
      shares will by issued under US securities laws and will be subject to
      restrictions as set out by the securities and exchanges
  commission.

	 	 	 	 
	4. 	
      CONFIDENTIALITY

	 	 	 	 
	4.1 	
      The Consultant shall not, either during the continuance
      of this agreement or for not less than one year thereafter make personal
      use of or divulge to any other company, firm or person any confidential
      information received by virtue of this Agreement or any market or other
      information relating to the business of the Company.

	 	 	 	 
	5. 	
      TERMINATION

	 	 	 	 
	5.1 	
      This Agreement may be terminated in accordance with
      clause 1 hereof by either party giving one month’s written notice to the
      other party in the following circumstances;

	 	 	 	 
		(a) 	
      if either party commits or causes to be committed any
      material breach of its obligations under the Agreement provided that in
      the case of a breach capable of remedy the non-defaulting party shall have
      first given written notice to the defaulting party specifying the breach
      complained of any requiring the same to be remedied within a reasonable
      period of time from notification thereof and the defaulting party shall
      have failed to comply therewith;

	 	 	 	 
		(b) 	
      if either party commits an act of insolvency,
      including:

	 	 	 	 
			i. 	
      making a general assignment for the benefit of, or
      entering into a reorganisation, arrangement, or composition with
      creditors, or

	 	 	 	 
			ii. 	
      admitting in writing that it is unable to pay its debts
      as they become due, or

	 	 	 	 
			iii. 	
      seeking, consenting to or acquiescing in the appointment
      of any trustee, administrator, receiver or liquidator or analogous officer
      of it or any material part of its property, or

	 	 	 	 
			iv. 	
      the presentation or filing of a petition in respect of it
      (other than by the other party to this Agreement in respect of any
      obligation under this Agreement) in any court or before any agency
      alleging or for the bankruptcy, winding-up or insolvency of such party (or
      any analogous proceeding) or seeking any reorganisation, arrangement.,
      composition, readjustment, administration, liquidation, dissolution or
      similar relief under any present or future stature, law or resolution,
      such petition (except in the case of a petition for winding-up or any
      analogous proceeding in respect of which no such 30 day period shall apply
      not having been stayed or dismissed within 30 days of its
  filing;

	 	v. 	
      the appointment of a receiver, administrator, liquidator
      or trustee or analogous officer of such party over all or any material
      part of such party’s property.

	6. 	
      ASSIGNMENT

	 	 
	6.1 	
      This Agreement may not be assigned by either party
      without the prior written consent of the other party.

	 	 
	7. 	
      AMENDMENT

	 	 
	7.1 	
      This Agreement may not be amended except by the written
      consent of both parties.

	 	 
	8. 	
      NOTICES

	 	 
	8.1 	
      All notices required to be delivered under this agreement
      by one party to the other shall be sent in writing to the addresses as are
      set forth at the beginning of this agreement, or such address as the
      parties shall thereafter provide to each other in writing.

	 	 
	9. 	
      GOVERNING LAW

	 	 
	9.1 	
      The Agreement shall be governed by and constructed in
      accordance with the laws of the United States of America. Any disputes
      which may arise out of this Agreement, if not resolved amicably between
      the parties, shall be settled finally before the courts of the United
      States of America.

DATED THE 1st DAY OF December, 2007 

ATTESTATIONS

Signed as a deed by a DIRECTOR or the COMPANY SECRETARY

	on behalf of 	/s/ David Cooper 
	 	 
	NEXTGEN BIOSCIENCE INC. 	 
    

	Signed as a deed by 	/s/ Dr. Wang Chong 
	 	 
	Dr Wang ChongFiled by Automated Filing Services Inc. (604) 609-0244 - Nextgen Biosciences Inc. - Exhibit 10.8

EXHIBIT 10.8

CONSULTANCY AGREEMENT

PARTIES

(1) NEXTGEN BIOSCIENCE INC., whose office is located at,
46 Aldgate High Street, EC3N 1AL London, U.K. (the “Company”)

(2) Anders Boegh Jensen, of Ejlersvej 13, DK-3050
Humlebaek, Denmark (the “Consultant”)

WHEREAS

	(A) 	
      The Consultant has agreed to provide, for a period of two
      years, consultancy services to the Company in the area of scientific
      advice in connection with the business of the evaluation, acquisition and
      development of patents in the field of healthcare drug treatments offered
      by the Company and its associated companies (the “Business”).

	 	 
	(B) 	
      The parties have agreed that this agreement shall govern
      the terms of the services to be provided by the
  Consultant.

OPERATIVE PROVISIONS

	1. 	
      DURATION OF APPOINTMENT

	 	 	 
	1.1 	
      The Consultant shall continue to provide the consultancy
      service to the Company on the terms of this agreement for a term from
      1st December 2007 for a fixed term of two years unless or until
      terminated under the provisions of Clause 5.1 hereafter. The parties may
      extend the term of this Agreement for a further term of twelve months by
      mutual written agreement.

	 	 	 
	2. 	
      DUTIES

	 	 	 
	2.1 	
      The services of the Consultant shall comprise the giving
      of advice to the Company in the area of scientific advice via the
      Scientific Advisory Board of the Company (“Advisory Board” or “SAB”)) in
      connection with the Business and such other advisory services as may be
      agreed between the parties.

	 	 	 
	2.2 	
      The Consultant shall be accountable to the Company’s CEO
      and shall in performance of his role hereunder:

	 	 	 
		(a) 	
      Use his best endeavours to advise the Company via the
      Advisory Board when required in the areas described in 2.1
above;

	 	 	 
		(b) 	
      Conduct such travelling as shall be reasonably necessary
      to advise the Business;

	 	 	 
		(c) 	
      Carry out his duties in good faith and in proper and
      efficient manner;

	 	 	 
		(d) 	
      Conduct himself with propriety and not bring the Company
      into disrepute;

	 	 	 
		(e) 	
      Not have any authority to bind the Company in any way and
      shall not hold himself out either by words or conduct as being the agent
      of the Company;

	 	(f) 	
      Act as a member of the Advisory Board of the Company,
      attending meetings where possible of such advisory board when held in
      London or other cities in Europe; and

	 	 	 
	 	(g) 	
      Not misrepresent the Company to any
  person.

	3. 	
      FEES

	 	 	 	 
	3.1 	
      The Consultant shall be not entitled to receive from the
      Company any fixed cash fees for the services outlined herein, but shall be
      entitled to receive reimbursement of any and all expenses properly
      incurred in performing his duties hereunder.

	 	 	 	 
	3.2 	
      The Consultant will receive, as payment in kind from the
      Company, in respect of his services under this Agreement, the issue to him
      of 2,000,000 shares in the Company. The Consultant undertakes that the
      shares will by issued under US securities laws and will be subject to
      restrictions as set out by the securities and exchanges
  commission.

	 	 	 	 
	4. 	
      CONFIDENTIALITY

	 	 	 	 
	4.1 	
      The Consultant shall not, either during the continuance
      of this agreement or for not less than one year thereafter make personal
      use of or divulge to any other company, firm or person any confidential
      information received by virtue of this Agreement or any market or other
      information relating to the business of the Company.

	 	 	 	 
	5. 	
      TERMINATION

	 	 	 	 
	5.1 	
      This Agreement may be terminated in accordance with
      clause 1 hereof by either party giving one month’s written notice to the
      other party in the following circumstances;

	 	 	 	 
		(a) 	
      if either party commits or causes to be committed any
      material breach of its obligations under the Agreement provided that in
      the case of a breach capable of remedy the non-defaulting party shall have
      first given written notice to the defaulting party specifying the breach
      complained of any requiring the same to be remedied within a reasonable
      period of time from notification thereof and the defaulting party shall
      have failed to comply therewith;

	 	 	 	 
		(b) 	
      if either party commits an act of insolvency,
      including:

	 	 	 	 
			i. 	
      making a general assignment for the benefit of, or
      entering into a reorganisation, arrangement, or composition with
      creditors, or

	 	 	 	 
			ii. 	
      admitting in writing that it is unable to pay its debts
      as they become due, or

	 	 	 	 
			iii. 	
      seeking, consenting to or acquiescing in the appointment
      of any trustee, administrator, receiver or liquidator or analogous officer
      of it or any material part of its property, or

	 	 	 	 
			iv. 	
      the presentation or filing of a petition in respect of it
      (other than by the other party to this Agreement in respect of any
      obligation under this Agreement) in any court or before any agency
      alleging or for the bankruptcy, winding-up or insolvency of such party (or
      any analogous proceeding) or seeking any reorganisation, arrangement.,
      composition, readjustment, administration, liquidation, dissolution or
      similar relief under any present or future stature, law or resolution,
      such petition (except in the case of a petition for winding-up or any
      analogous proceeding in respect of which no such 30 day period
  shall

	 	 		 apply not having been stayed or dismissed within 30
        days of its filing;

	 	 	 	 
	 	 	v. 	 the appointment of a receiver, administrator, liquidator
        or trustee or analogous officer of such party over all or any material
        part of such party’s property.

	6. 	
      ASSIGNMENT

	 	 
	6.1 	
      This Agreement may not be assigned by either party
      without the prior written consent of the other party.

	 	 
	7. 	
      AMENDMENT

	 	 
	7.1 	
      This Agreement may not be amended except by the written
      consent of both parties.

	 	 
	8. 	
      NOTICES

	 	 
	8.1 	
      All notices required to be delivered under this agreement
      by one party to the other shall be sent in writing to the addresses as are
      set forth at the beginning of this agreement, or such address as the
      parties shall thereafter provide to each other in writing.

	 	 
	9. 	
      GOVERNING LAW

	 	 
	9.1 	
      The Agreement shall be governed by and constructed in
      accordance with the laws of the United States of America. Any disputes
      which may arise out of this Agreement, if not resolved amicably between
      the parties, shall be settled finally before the courts of the United
      States of America.

DATED THE 1st DAY OF December, 2007 

ATTESTATIONS

Signed as a deed by a DIRECTOR or the COMPANY SECRETARY on
behalf of

	NEXTGEN BIOSCIENCE INC. 	/s/
      David Cooper 

	Signed as a deed by 	  
	 	 
	Anders Boegh Jensen 	/s/
      Anders Boegh Jensen

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}]]